¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-06-21

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-06-21
±³À°ÀÏÀÚ : 2024-06-21
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ ÄÁº¥¼ÇȦ4F

±³À°ÁÖÁ¦ : 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ(1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ

´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520

À̸ÞÀÏ : retina@retina.or.kr

±³À°Á¾·ù : ¾È°ú

Âü¼®¿¹»óÀÎ : 170¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 34ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:00~14:08 (ÃÊ·Ï)Exosomes Derived from Adipose-Derived Mesenchymal Stem Cells Alleviates Apoptosis and Oxidative Stress of Retinal Pigment Epithelial Cells Through Activation of Nrf2 Signaling Pathway ¸¶´ëÁß(ÇѸ²´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:08~14:16 (ÃÊ·Ï)RPE senescence driven by dysregulation of cell-matrix adhesion Á¤Çý¿ø(°Ç±¹´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:16~14:24 (ÃÊ·Ï)Immune modulatory and anti-angiogenic effects of cathepsin S knockdown in age-related macular degeneration ±èÁöÅÃ(Áß¾Ó´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:24~14:32 (ÃÊ·Ï)Çѱ¹ÀÎ À¯Àüü¿¡¼­ Alu element »ðÀÔ ºÐ¼® ÁÖ±¤½Ä(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:32~14:40 (ÃÊ·Ï)Iron's Influence: modulation of bisretinoids in the Retina ±èÇýÁø(°è¸í´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:40~14:48 (ÃÊ·Ï)Decrease of Crystallins by miR-325-3p in retinal cells under blue light ¹Ú¿µÈÆ(°¡Å縯´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:48~14:56 (ÃÊ·Ï)Intravitreal injectable hydrogel rods with long-acting anti-VEGF delivery to the retina ¿ì¼¼ÁØ(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 14:56~15:04 (ÃÊ·Ï)Three-Year Outcomes of Polypoidal Choroidal Vasculopathy Treatment According to Early Polypoidal Regression: Characteristics of Polypoidal Lesions on Swept-Source Optical Coherence Tomography Angi ÃÖÀçȯ(°æÈñ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 15:04~15:12 (ÃÊ·Ï)Digoxin-induced retinal toxicity: multimodal imaging and clinical features °­Çö±¸(¿¬¼¼´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 15:12~15:20 (ÃÊ·Ï)Initial Real-World Experience with Faricimab in treatment-naïve Neovascular Age-Related Macular Degeneration Àå¿ìÇõ(Àå¿ìÇõ¾È°ú)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 15:20~15:28 (ÃÊ·Ï)Choroidal vascular alterations using ultra-widefield indocyanine green angiography in central serous chorioretinopathy after photodynamic therapy »ç°ø¹Î(¿µ³²´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 15:28~15:36 (ÃÊ·Ï)Double trouble? Implications of concurrent different drusen subtypes in age-related macular degeneration ¾ÈÁöÀ±(¼­¿ï´ë)

ÈÞ½Ä 06¿ù 21ÀÏ 15:36~15:52 ÈÞ½Ä -(-)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 15:52~16:00 (ÃÊ·Ï)Pneumatic Retinopexy for Rhegmatogenous Retinal Detachment and its Pitfall °­°æÅÂ(°æºÏ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:00~16:08 (ÃÊ·Ï)Modified sutureless flange intraocular lens fixation (twist technique) with reduced surgical time and risk ±ÇÀ±Çü(µ¿¾Æ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:08~16:16 (ÃÊ·Ï)Amniotic Membrane Transplantation in Refractory Macular Hole: Closure Pattern in Case Series ÃÖ¹ÌÇö(°í·Á´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:16~16:24 (ÃÊ·Ï)Macular Buckling Surgery Using an Intraoperative Optical Coherence Tomography -assisted Novel L-shaped Buckle for Patients with Myopic Tractional Maculopathy ¾çÁö¸í(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:24~16:32 (ÃÊ·Ï)¸Á¸·¼ö¼úÈÄ ¸Á¸·ÇϾ×ÀÇ Àå±âº¯µ¿¿¡ °üÇÑ °íÂû °­¼¼¿õ(¼º±Õ°ü´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:32~16:40 (ÃÊ·Ï)Comparison of Clinical Outcomes between Two Flanged Intraocular Lens (IOL) Fixation Techniques: IOL exchange versus IOL reposition µµÀç·Ï(°æºÏ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:40~16:45 (ÃÊ·Ï)RP´Â ¸ðµÎ °á±¹ ½Ç¸íÇϳª¿ä? À¯Àü¼º ¸Á¸·ÁúȯÀÌ ÀÖ´Â 900¸íÀÇ Çѱ¹ÀÎ WES µ¥ÀÌÅ͸¦ ¹ÙÅÁÀ¸·Î ÇÑ °æÇÑ ÀÓ»ó¾ç»óÀ» º¸À̴ ȯÀÚÀÇ À¯ÀüÀû Ư¼º ºÐ¼® Àü¼ÒÈñ(Ä«À̾Ȱú)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:45~16:50 (ÃÊ·Ï)Early Developmental Characteristics and Features of a Three-Dimensional Retinal Organoid Model of X-Linked Juvenile Retinoschisis ÇÑÁ¤¿ì(¼øõÇâ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:50~16:55 (ÃÊ·Ï)Metabolic dysregulation of BRB in retinitis pigmentosa ÀÌ»óÁØ(°í½Å´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 16:55~17:00 (ÃÊ·Ï)A Novice Retina Surgeon's Journey to Scleral Fixation ±èÁØÇü(Â÷ÀÇ°ú´ëÇÐ)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:00~17:05 (ÃÊ·Ï)RPGR-associated X-linked Retinitis Pigmentosa in Female Carriers and the Role of Skewed X Chromosome Inactivation Ȳ¼º¼ø(¼º±Õ°ü´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:05~17:10 (ÃÊ·Ï)Increased Risk of Maculopathy in Patients with Pentosan Polysulfate Use in the Korean Population: A 12-Year Nationwide Cohort Study ±è¹Î¼®(¼­¿ï´ë)

Åä·Ð 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:10~17:15 q&a ¿¬ÀÚ6¸í(¿¬ÀÚ6¸í)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:15~17:20 (ÃÊ·Ï)Initial subfoveal choroidal thickness reduction as a predictive factor for 1-year treatment interval in neovascular age-related macular degeneration patients treated with aflibercept ÀÌÁ¤Çå(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:20~17:25 (ÃÊ·Ï)GPR143 mutation¿Í macular degenerationÀÇ ¿¬°ü¼º ÀåÁöÇý(°è¸í´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:25~17:30 (ÃÊ·Ï)Modified Sutureless Flanged Intraocular Lens Scleral Fixation Approach Accessible for Novice Retinal Surgeons Ȳº¸ÀÎ(°¡Å縯´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:30~17:35 (ÃÊ·Ï)ÀÌ»óÀûÀÎ À¯¸®Ã¼ÀýÁ¦¼ö¼ú ȯ°æÀ» À§ÇÑ ¸î°¡Áö °³¼±Á¡ ±èÁ¾¿í(¿ì¸®¾È°ú)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:35~17:40 (ÃÊ·Ï)ÀÌ ºÐÀ» À§ÇÑ °¡Àå ÁÁÀº ÇØ°áÃ¥Àº ¹«¾ùÀϱî¿ä? Proliferative retinopathy with tractional retinal detachment and vitreomacular traction syndrome in one-eye diabetes mellitus patient ÀÌÁ¤È£(Àߺ¸´Â¾È°úÀÇ¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:40~17:45 (ÃÊ·Ï)A case of Eales¡¯ disease misdiagnosed as non-typical Persistent Hyperplastic Primary Vitreous(PHPV) -ºñÀüÇüÀûÀÎ PHPV·Î ¿ÀÀÎÇÑ ÀϽºº´ Áõ·Ê ¹é½Â±¹(¸ðµÎÀÇ ¾È°ú)

Åä·Ð 06¿ù 21ÀÏ 4F ÄÁº¥¼ÇȦ 17:45~17:50 q&a ¿¬ÀÚ6¸í(¿¬ÀÚ6¸í)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-06-21""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û »ï¼º¼­¿ïº´¿ø The 21th SMC STROKE SYMPOSIUM, 2024 : 2024-06-22
´ÙÀ½±Û 2024³â °áÇÙ°ü¸®±³À° 2±â(2ÀÏÂ÷) : 2024-06-21
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
138 ¼­¿ï Á¦14ȸ ÀÓ»óÀÌ°úÇм¼¹Ì³ª(´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ&´ëÇÑÀÌÇÐȸ °øµ¿ÁÖ°ü) : 2018-08-26 0 654 2018-07-28
137 ¼­¿ï Áß¾Ó´ëÇб³º´¿ø Á¦4ȸ Áß¾Ó´ëÇб³ ¼Ò¾Æû¼Ò³â°ú ¿¬¼ö°­Á : 2018-08-26 0 478 2018-07-28
136 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø 13th Yonsei Foot & Ankle Cadaveric Workshop : 2018-08-26 0 409 2018-07-28
135 °æ±â Á¦59ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ¼¼¹Ì³ª : 2018-08-26 0 1,844 2018-07-28
134 ¼­¿ï Á¦8ȸ »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â¼¾ÅÍ ½ÉÆ÷Áö¾ö(ÁÖÁ¦: ÈçÈ÷ ¸¸³ª°Ô µÇ´Â ¼Ò¾Æû¼Ò³â Áúȯ) : 2018-08-26 0 723 2018-07-28
133 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Á¦9ȸ ¿¬¼¼ÀÇ´ë ¼Ò¾Æ°úÇб³½Ç, ¼Ò¾Æ¾Ë·¹¸£±âÈ£Èí±âÁúȯ ¿¬¼ö°­Á : 2018-08-26 0 395 2018-07-28
132 ¼­¿ï 2018 ´ëÇѼö¸éÇÐȸ ¿öÅ©¼¥ : 2018-08-26 0 482 2018-07-28
131 °æºÏ ´ëÇѼҾưúÇÐȸ ¼Ò¾Æû¼Ò³â°ú ¿Ü·¡¿¡¼­ Àû¿ë °¡´ÉÇÑ ÀÓ»óÁö½Ä : 2018-08-26 0 652 2018-07-28
130 °æ³² ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ 2018 Post Graduate Asthma School (2ÀÏÂ÷) : 2018-08-26 0 1,080 2018-07-28
129 ¼­¿ï Á¦5ȸ ´ëÇÑ°³¿ø³»°úÀÇ»çȸ °¨¿°º´ ¹× ¹é½Å½ÉÆ÷Áö¿ò : 2018-08-26 0 527 2018-07-28
128 ¼­¿ï Á¦15Â÷ °æ±âµµÀÇ»çȸ Çмú´ëȸ : 2018-08-26 0 1,154 2018-07-28
127 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ °í/½½°üÀý Áúȯ : 2018-08-25 0 565 2018-07-28
126 ºÎ»ê ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018 ECMO Symposium and Simulation Workshop : 2018-08-25 0 2,513 2018-07-28
125 ´ëÀü 2018³â ´ëÇÑÅëÁõÇÐȸ Áö¹æ¼øȸ ÃÊÀ½ÆÄ ¹× °æ¸·¿Ü³»½Ã°æWorkshop_ÃÊÀ½ÆÄ¿öÅ©¼ó : 2018-08-25 0 629 2018-07-28
124 ´ëÀü Ãæ³²´ëÇб³º´¿ø Ãæ³²´ëÇб³ ½Å°æ¿Ü°ú ȨĿ¹Ö ½ÉÆ÷Áö¿ò : 2018-08-25 0 902 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷